Pfizer Inc. Q3 2025 Earnings Recap

PFE Q3 2025 November 5, 2025

Pfizer reported strong third-quarter 2025 results, leveraging strategic partnerships and clinical advancements to enhance its competitive position in the pharmaceutical landscape.

Earnings Per Share Beat

$0.87 vs $0.63 est.

+37.4% surprise

Revenue Beat

16654000000 vs 16498101464 est.

+0.9% surprise

Market Reaction

1-Day +0.98%

5-Day +5.12%

30-Day +4.71%

Key Takeaways

Established a landmark agreement with the U.S. government, addressing key policy impacts and committing to U.S. manufacturing investments.
Advanced the proposed acquisition of Metsera, with potential to enhance Pfizer’s portfolio in obesity treatments despite external competitive offers.
Received encouraging Phase II clinical data for SSGJ-707, with plans for a robust clinical development program to unlock its potential.
Presented breakthrough results at ESMO from multiple oncology studies, reinforcing portfolio strength and expanding addressable patient populations across various cancer types.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit PFE on AllInvestView.